Elanco Animal Health: 3 Key Takeaways for Long-Term Investors

On its third-quarter 2026 earnings call, held on Nov. 6, 2026, Elanco Animal Health (NYSE:ELAN) announced revenue grew 11% year over year to $1.265 billion. Balance sheet deleveraging and pricing power are lifting operating margins while new veterinary treatments gain market share.

Three takeaways from the call highlight how management plans to capture long-term growth.

1. Debt Reduction Unlocks Capital Allocation Flexibility

Lowering gross debt by $216 million in the third quarter brought net leverage below 3.0 times earnings before interest, taxes, depreciation, and amortization (EBITDA), meeting a key balance sheet target ahead of schedule. Improving free cash flow gives Elanco Animal Health greater room to fund organic growth initiatives.

Achieving the sub-3.0 times milestone accelerates our capital allocation flexibility, we advance toward our target of 2 to 2.5x.
-- Robert VanHimbergen, Executive Vice President and Chief Financial Officer

2. Differentiated Innovation Drives Pricing Power Over Discounting

Pet health product prices increased by 5% in the third quarter, while volume rose by 9%, indicating that proprietary treatments command full value in the clinic. Management is avoiding price cuts even as industry rivals use temporary promotional discounts.

Elanco has not, will not, and does not expect a need for our participation in aggressive price competition to grow and gain share.
-- Jeffrey N. Simmons, President and Chief Executive Officer

3. Efficiency Programs Target Long-Term Savings to Expand Margins

The Elanco Ascend initiative aims to improve profitability through procurement savings, operational automation, and artificial intelligence in research and development. These measures helped expand adjusted gross margin three percentage points to 56.1% in the quarter.

[We] continue to advance our Elanco Ascend productivity initiatives, targeting $200 million to $250 million in total adjusted EBITDA savings by 2030.
-- Robert VanHimbergen, Executive Vice President and Chief Financial Officer

Looking Ahead

Momentum is building across key treatment categories as new veterinary launches expand clinic penetration. Operational scale and a diversified portfolio spanning farm animals and pets provide structural growth drivers, while management watches regional livestock cycles and inflation pressures.

We have made rapid progress to gain a foothold in the broad spectrum in decto and derm, with each market over $2 billion in size.
-- Jeffrey N. Simmons, President and Chief Executive Officer

Expanding distribution partnerships and continuous manufacturing improvements position the business to capture long-term market share.

We have a long runway to win share while the markets continue to grow.
-- Jeffrey N. Simmons, President and Chief Executive Officer

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.